NASDAQ:CERE Cerevel Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $28.15 -0.48 (-1.68%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$27.81▼$29.3450-Day Range$20.62▼$33.2752-Week Range$12.50▼$46.16Volume1.80 million shsAverage Volume472,454 shsMarket Capitalization$4.17 billionP/E RatioN/ADividend YieldN/APrice Target$41.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CERE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CERE Stock Forecast (MarketRank)Overall MarketRank™1.84 out of 5 starsMedical Sector745th out of 1,418 stocksPharmaceutical Preparations Industry362nd out of 679 stocksAnalyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 - 3.4 Analyst's Opinion Consensus RatingCerevel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.00, Cerevel Therapeutics has a forecasted upside of 45.6% from its current price of $28.15.Amount of Analyst CoverageCerevel Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.9 Community Rank Outperform VotesCerevel Therapeutics has received 142 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCerevel Therapeutics has received 52 “underperform” votes. (Add your “underperform” vote.)Community SentimentCerevel Therapeutics has received 73.20% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cerevel Therapeutics and other stocks. Vote “Outperform” if you believe CERE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CERE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCerevel Therapeutics does not currently pay a dividend.Dividend GrowthCerevel Therapeutics does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerevel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,909,250.00 in company stock.Percentage Held by InsidersOnly 3.60% of the stock of Cerevel Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($1.94) to ($2.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerevel Therapeutics is -16.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerevel Therapeutics is -16.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerevel Therapeutics has a P/B Ratio of 7.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cerevel Therapeutics (NASDAQ:CERE)Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.Read More CERE Stock News HeadlinesJune 15, 2022 | finance.yahoo.comCerevel Therapeutics Announces Updates to its Board of DirectorsJune 12, 2022 | americanbankingnews.comCerevel Therapeutics (NASDAQ:CERE) Shares Gap Down to $28.02June 7, 2022 | finance.yahoo.comDoes Early Life Inflammation Contribute to the Risk for Developing Psychiatric Conditions?June 5, 2022 | americanbankingnews.comCerevel Therapeutics (NASDAQ:CERE) Shares Gap Up to $27.03May 25, 2022 | finance.yahoo.comCerevel Therapeutics to Present at the Jefferies Healthcare ConferenceMay 14, 2022 | seekingalpha.comCerevel Therapeutics Holdings, Inc. (CERE) CEO Tony Coles on Q1 2022 Results - Earnings Call TranscriptMay 11, 2022 | seekingalpha.comCerevel Therapeutics Holdings, Inc. 2022 Q1 - Results - Earnings Call PresentationMay 11, 2022 | finance.yahoo.comHere's Why We're Not Too Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn SituationMay 10, 2022 | seekingalpha.comCerevel Therapeutics GAAP EPS of -$0.46May 10, 2022 | finance.yahoo.comCerevel Therapeutics Reports First Quarter 2022 Financial Results and Business UpdatesMay 9, 2022 | nasdaq.comRSI Alert: Cerevel Therapeutics Holdings (CERE) Now OversoldApril 28, 2022 | finance.yahoo.comWhat investors can learn from the carnage in SPACs: Morning BriefApril 13, 2022 | finance.yahoo.comCerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryCoal & Consumable Fuels SectorMedical Current SymbolNASDAQ:CERE CUSIP15677310 CIK767884 Webceres.net Phone844-304-2048FaxN/AEmployees200Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today6/24/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$41.00 High Stock Price Forecast$50.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+45.6%Consensus RatingModerate Buy Rating Score (0-4)2.83333333333333 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-225.33 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.97% Return on Assets-39.91% Debt Debt-to-Equity RatioN/A Current Ratio15.67 Quick Ratio15.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.92 per share Price / Book7.18Miscellaneous Outstanding Shares148,289,000Free Float142,951,000Market Cap$4.17 billion OptionableNot Optionable Beta2.79 Cerevel Therapeutics Frequently Asked Questions Should I buy or sell Cerevel Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Cerevel Therapeutics stock. View analyst ratings for Cerevel Therapeutics or view top-rated stocks. What is Cerevel Therapeutics' stock price forecast for 2022? 6 Wall Street research analysts have issued 1-year target prices for Cerevel Therapeutics' shares. Their CERE stock forecasts range from $20.00 to $50.00. On average, they anticipate Cerevel Therapeutics' share price to reach $41.00 in the next twelve months. This suggests a possible upside of 45.6% from the stock's current price. View analysts' price targets for Cerevel Therapeutics or view top-rated stocks among Wall Street analysts. How has Cerevel Therapeutics' stock performed in 2022? Cerevel Therapeutics' stock was trading at $32.42 at the beginning of the year. Since then, CERE stock has decreased by 13.2% and is now trading at $28.15. View the best growth stocks for 2022 here. When is Cerevel Therapeutics' next earnings date? Cerevel Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for Cerevel Therapeutics. How were Cerevel Therapeutics' earnings last quarter? Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) posted its earnings results on Tuesday, May, 10th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.02. During the same period in the prior year, the firm earned ($0.40) earnings per share. View Cerevel Therapeutics' earnings history. Who are Cerevel Therapeutics' key executives? Cerevel Therapeutics' management team includes the following people: Dr. N. Anthony Coles Jr., M.P.H., CEO & Exec. Chairman (Age 62, Pay $1.24M)Dr. John J. Renger Ph.D., Chief Scientific Officer (Age 53, Pay $945.08k)Ms. Kathleen Tregoning M.A., Chief Corp. Affairs Officer (Age 51, Pay $600.79k)Mr. Abraham N. Ceesay M.B.A., Pres (Age 44)Mr. Mark Bodenrader, Interim CFO, VP of Fin. & Chief Accounting Officer (Age 49)Mr. Matthew Calistri, VP of Investor RelationsMr. Scott M. Akamine J.D., Chief Legal Officer (Age 38)Mr. Kenneth A. DiPietro, Chief HR Officer (Age 63)Dr. Ramiro Sanchez, Chief Medical Officer (Age 61) Who are some of Cerevel Therapeutics' key competitors? Some companies that are related to Cerevel Therapeutics include CNX Resources (CNX), Arch Resources (ARCH), Warrior Met Coal (HCC), Uranium Energy (UEC), Hallador Energy (HNRG), Cloud Peak Energy (CLDPQ), KiOR (KIORQ) and Uranerz Energy (URZ). View all of CERE's competitors. What other stocks do shareholders of Cerevel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO). What is Cerevel Therapeutics' stock symbol? Cerevel Therapeutics trades on the NASDAQ under the ticker symbol "CERE." Who are Cerevel Therapeutics' major shareholders? Cerevel Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.25%), BlackRock Inc. (2.29%), State Street Corp (1.46%), Rock Springs Capital Management LP (1.16%), Lord Abbett & CO. LLC (0.49%) and Northern Trust Corp (0.28%). Company insiders that own Cerevel Therapeutics stock include Gabrielle Sulzberger, John Renger and Perceptive Advisors Llc. View institutional ownership trends for Cerevel Therapeutics. Which major investors are selling Cerevel Therapeutics stock? CERE stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., UBS Group AG, Affinity Asset Advisors LLC, Citigroup Inc., BlackRock Inc., State Street Corp, JPMorgan Chase & Co., and Bank of New York Mellon Corp. View insider buying and selling activity for Cerevel Therapeutics or view top insider-selling stocks. Which major investors are buying Cerevel Therapeutics stock? CERE stock was bought by a variety of institutional investors in the last quarter, including Ally Bridge Group NY LLC, Candriam Luxembourg S.C.A., Woodline Partners LP, Alyeska Investment Group L.P., The Manufacturers Life Insurance Company , Verition Fund Management LLC, Verition Fund Management LLC, and Rock Springs Capital Management LP. Company insiders that have bought Cerevel Therapeutics stock in the last two years include Gabrielle Sulzberger, and Perceptive Advisors Llc. View insider buying and selling activity for Cerevel Therapeutics or or view top insider-buying stocks. How do I buy shares of Cerevel Therapeutics? Shares of CERE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cerevel Therapeutics' stock price today? One share of CERE stock can currently be purchased for approximately $28.15. How much money does Cerevel Therapeutics make? Cerevel Therapeutics (NASDAQ:CERE) has a market capitalization of $4.17 billion. The biotechnology company earns $-225.33 million in net income (profit) each year or ($1.71) on an earnings per share basis. How many employees does Cerevel Therapeutics have? Cerevel Therapeutics employs 200 workers across the globe. How can I contact Cerevel Therapeutics? Cerevel Therapeutics' mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The official website for Cerevel Therapeutics is ceres.net. The biotechnology company can be reached via phone at 844-304-2048 or via email at [email protected]. This page (NASDAQ:CERE) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
